Patients with COPD plus a depression/anxiety disorder had poorer scores related to disease burden and health-related quality of life, according to data published in Chronic Obstructive Pulmonary ...

The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

•呼吸无界 全球智汇--COPD 国际专家巡讲活动，于 3 月 18 日盛大启航。•本次学术盛会特邀 GOLD 主席 Alvar Agusti 教授、英国伦敦大学学院呼吸医学专家 John Hurst 教授、伦敦国王学院呼吸内科权威 Richard ...

Inhaled corticosteroids (ICS) are commonly prescribed for chronic obstructive pulmonary disease (COPD), but not recommended ...

Adults with arthritis and chronic obstructive pulmonary disease (COPD) have a higher risk for mortality than individuals without COPD.

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

The global COPD and asthma diagnostic and monitoring device market accounted for $4,953.60 million in 2019, and is expected to reach $8,202.62 million by 2027, registering a CAGR of 6.3% from 2020 to ...

Adults who had an above-average BMI, overweight or obesity during childhood have increased risk for developing chronic ...

Long-term inhaled corticosteroid (ICS) use for chronic obstructive pulmonary disease/ COPD (lung disease) may increase the ...

GSK plc GSK announced that the European Medicines Agency (“EMA”) has accepted for review a regulatory filing, seeking ...

Genetic factors may affect the functional status of patients with chronic obstructive pulmonary disease (COPD).

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.